Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels

Prostate International

Volumn 3, Issue 1, 2015, Pages 10-15

  Koo, Kyo Chul ^a   Park, Sang Un ^a   Kim, Ki Hong ^a   Rha, Koon Ho ^a   Hong, Sung Joon ^a   Yang, Seung Choul ^a   Chung, Byung Ha ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Alkaline phosphatase; Bone; Metastasis; Prostate cancer; Prostate specific antigen; Survival

Indexed keywords

ALKALINE PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; BONE LESION; BONE METASTASIS; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE SCORE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; VERY ELDERLY; VISUAL ANALOG SCALE;

EID: 84928250715     PISSN: 22878882     EISSN: 2287903X     Source Type: Journal    
DOI: 10.1016/j.prnil.2015.02.006     Document Type: Article

References (30)

1. A.V. D'Amico, K. Cote, M. Loffredo, A.A. Renshaw, and D. Schultz Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 2002 4567 4573
2. M. Norgaard, A.O. Jensen, J.B. Jacobsen, K. Cetin, J.P. Fryzek, and H.T. Sorensen Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007) J Urol 184 2010 162 167
3. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 2006 6243s 6249s
4. J. Sturge, M.P. Caley, and J. Waxman Bone metastasis in prostate cancer: emerging therapeutic strategies Nat Rev Clin Oncol 8 2011 357 368
5. E.D. Crawford, C.L. Bennett, G.L. Andriole, M.B. Garnick, and D.P. Petrylak The utility of prostate-specific antigen in the management of advanced prostate cancer BJU Int 112 2013 548 560
6. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group J Clin Oncol 26 2008 1148 1159
7. Y.C. Ou, J.T. Chen, C.L. Cheng, H.C. Ho, and C.R. Yang Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml Jpn J Clin Oncol 33 2003 574 579
8. M.R. Feneley, and A.W. Partin Indicators of pathologic stage of prostate cancer and their use in clinical practice Urol Clin North Am 28 2001 443 458
9. G. Rodrigues, K. Bae, and M. Roach et al. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two radiation therapy oncology group prostate clinical trials Int J Radiat Oncol Biol Phys 80 2011 445 452
10. M. Roach 3rd, J. Lu, and M.V. Pilepich et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627
11. A.S. Alexander, A. Mydin, and S.O. Jones et al. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA) >40 ng/ml: prognostic significance of the preradiation PSA nadir Int J Radiat Oncol Biol Phys 81 2011 e713 e719
12. C.J. Logothetis, N.M. Navone, and S.H. Lin Understanding the biology of bone metastases: key to the effective treatment of prostate cancer Clin Cancer Res 14 2008 1599 1602
13. A.J. Armstrong, and P.G. Febbo Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature Oncologist 14 2009 816 827
14. M.R. Smith, R. Cook, K.A. Lee, and J.B. Nelson Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer Cancer 117 2011 2077 2085
15. L.M. Demers, L. Costa, and A. Lipton Biochemical markers and skeletal metastases Cancer 88 2000 2919 2926
16. R.E. Coleman, P. Major, and A. Lipton et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 2005 4925 4935
17. O. Smaletz, H.I. Scher, and E.J. Small et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 2002 3972 3982
18. G.W. Chodak, N.J. Vogelzang, R.J. Caplan, M. Soloway, and J.A. Smith Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex study group JAMA 265 1991 618 621
19. S. Halabi, E.J. Small, and P.W. Kantoff et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
20. C. Kwak, S.J. Jeong, M.S. Park, E. Lee, and S.E. Lee Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J Urol 168 2002 995 1000
21. T. Sasaki, T. Onishi, and A. Hoshina Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis Prostate Cancer Prostatic Dis 14 2011 248 252
22. H.I. Scher, M.J. Morris, E. Basch, and G. Heller End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice J Clin Oncol 29 2011 3695 3704
23. F. Saad, S. Segal, and J. Eastham Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid Eur Urol 65 2014 146 153
24. R.W. Ross, W. Xie, and M.M. Regan et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect Cancer 112 2008 1247 1253
25. S.Y. Hong, D.S. Cho, S.I. Kim, H.S. Ahn, and S.J. Kim Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer Korean J Urol 53 2012 607 613
26. J. Morote, S. Esquena, and J.M. Abascal et al. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer Int J Biol Markers 20 2005 209 216
27. T.K. Choueiri, W. Xie, and A.V. D'Amico et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy Cancer 115 2009 981 987
28. T.A. Stamey, J.N. Kabalin, M. Ferrari, and N. Yang Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients J Urol 141 1989 1088 1090
29. Y. Furuya, S. Akimoto, and K. Akakura et al. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer Urol Int 60 1998 28 32
30. Y.H. Park, I.S. Hwang, C.W. Jeong, H.H. Kim, S.E. Lee, and C. Kwak Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer J Urol 181 2009 2520 2524